PharmaBoardroom

Interview: João Madeira – General Manager, Mylan Portugal

Experienced country manager, João Madeira, introduces Mylan’s new vision to be a global healthcare company serving patients across the world with…

The Trump Bounce for Pharma M&A

Blue-chip drug makers holding USD 200 billion in cash, mostly overseas, will start investing more of it in mergers and acquisitions (M&A) after…

Digital Assets: The Next “Must-Have” Acquisition for Big…

Digital health startups raised over USD six billion in equity financing in 2016, representing a five-year compound annual growth rate of 32 percent…

A Critical Juncture for the UK’s Vaccines Industry

Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market…

Interview: Thomas Bo Bjorn Klee – Managing Director,…

Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to…

Erik Nordkamp – Managing Director, Pfizer UK

Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping…

Interview: Silvia Guichardo – General Manager, GSK Portugal

Hailing from the Dominican Republic, Silvia Guichardo brings a fresh perspective as well as both US and Iberian experience to GSK Portugal. Six months…

Interview: Lucas Sigman – Director General, Chemo, Spain

Lucas Sigman, director general of Chemo, a leader in the research, development and manufacture of finished dosage forms and the active pharmaceutical…